Soluble urokinase plasminogen activator receptor measurements: influence of sample handling
- PMID: 11820717
- DOI: 10.1177/172460080101600402
Soluble urokinase plasminogen activator receptor measurements: influence of sample handling
Abstract
Aim: The influence of sample handling on soluble urokinase plasminogen activator receptor (suPAR) concentrations in serum and EDTA plasma was studied in 16 healthy premenopausal women.
Method: Blood was collected in dry tubes and tubes containing EDTA and kept at 4 degrees C or 20 degrees C for 1, 3, 8, 24 or 72 hours before processing into serum or EDTA plasma. In addition, serum and EDTA plasma were frozen and thawed 1-8 times. All suPAR measurements were performed by ELISA.
Results: No significant differences were found between serum or EDTA plasma suPAR concentrations when whole blood samples were kept for 1, 3, 8 or 24 hours. Significantly higher suPAR levels were found in samples kept for 72 hours at 20 degrees C compared to samples processed into serum or EDTA plasma after short-term storage for no more than 24 hours after collection. No significant differences were observed when whole blood was kept at 4 degrees C for up to 72 hours. Repeated freezing and thawing had no significant effect on the serum and EDTA plasma suPAR levels.
Conclusion: suPAR values in blood samples are dependent on the handling procedures of the samples. All samples of whole blood must be processed into EDTA plasma or serum within 24 hours if kept at 20 degrees C and within 72 hours if kept at 4 degrees C. However, repeated freezing/thawing cycles had no influence on suPAR values in the samples.
Similar articles
-
Evaluation of sample handling in relation to levels of tissue inhibitor of metalloproteinases-1 measured in blood by immunoassay.Int J Biol Markers. 2003 Jul-Sep;18(3):170-6. doi: 10.1177/172460080301800303. Int J Biol Markers. 2003. PMID: 14535586
-
Soluble urokinase plasminogen activator receptor in blood transfusion components.Transfus Med. 2004 Aug;14(4):305-12. doi: 10.1111/j.0958-7578.2004.00518.x. Transfus Med. 2004. PMID: 15285727
-
The prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) levels in stage III ovarian cancer patients.Anticancer Res. 2004 May-Jun;24(3b):1981-5. Anticancer Res. 2004. PMID: 15274388
-
Prognostic importance of the soluble plasminogen activator receptor, suPAR, in plasma from rectal cancer patients.Eur J Cancer. 2001 Mar;37(4):486-91. doi: 10.1016/s0959-8049(00)00422-6. Eur J Cancer. 2001. PMID: 11267858
-
The urokinase plasminogen activator receptor in blood from healthy individuals and patients with cancer.APMIS. 1999 Jan;107(1):160-7. doi: 10.1111/j.1699-0463.1999.tb01539.x. APMIS. 1999. PMID: 10190293 Review.
Cited by
-
Soluble Urokinase Plasminogen Activator Receptor Levels Are Associated with Severity of Fibrosis in Patients with Primary Sclerosing Cholangitis.J Clin Med. 2022 Apr 28;11(9):2479. doi: 10.3390/jcm11092479. J Clin Med. 2022. PMID: 35566603 Free PMC article.
-
Cardio-Renal Biomarker Soluble Urokinase-Type Plasminogen Activator Receptor Is Associated With Cardiovascular Death and Myocardial Infarction in Patients With Coronary Artery Disease Independent of Troponin, C-Reactive Protein, and Renal Function.J Am Heart Assoc. 2020 Apr 21;9(8):e015452. doi: 10.1161/JAHA.119.015452. Epub 2020 Apr 17. J Am Heart Assoc. 2020. PMID: 32299288 Free PMC article.
-
Soluble Urokinase Receptors in Focal Segmental Glomerulosclerosis: A Review on the Scientific Point of View.J Immunol Res. 2016;2016:2068691. doi: 10.1155/2016/2068691. Epub 2016 Jul 18. J Immunol Res. 2016. PMID: 27504461 Free PMC article. Review.
-
The accuracy of soluble urokinase-type plasminogen activator receptor for the diagnosis of neonatal sepsis: a meta-analysis.Front Med (Lausanne). 2023 Apr 27;10:1169114. doi: 10.3389/fmed.2023.1169114. eCollection 2023. Front Med (Lausanne). 2023. PMID: 37181361 Free PMC article. Review.
-
Increased soluble urokinase plasminogen activator levels modulate monocyte function to promote atherosclerosis.J Clin Invest. 2022 Dec 15;132(24):e158788. doi: 10.1172/JCI158788. J Clin Invest. 2022. PMID: 36194491 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous